Hubei Biocause Heilen Pharmaceutical (301211.SZ): Fiposidone tablets obtained drug registration certificate.
Hengdi Pharmaceutical (301211.SZ) announced that the company recently received the approval and issuance of the "Drug... by the National Medical Products Administration.
Hubei Biocause Heilen Pharmaceutical (301211.SZ) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the drug Febuxostat. Febuxostat is a xanthine oxidase inhibitor used primarily for long-term treatment of hyperuricemia and gout patients (including uric acid-lowering treatment after acute attacks of gouty arthritis).
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
